Sustained activation of the FGF1–MEK–ERK pathway inhibits proliferation, invasion and migration and enhances radiosensitivity in mouse angiosarcoma cells
Journal of Radiation Research · 2024
DOI: 10.1093/jrr/rrae021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Radiation Research, 2024. Verfasst von Taichi Miura und 4 weiteren Autor:innen. Beteiligte Einrichtung: Regenerative Therapy Research Group, Department of Radiation Regulatory Science Research, National Institute of Radiological Sciences (NIRS), Nationa…. Hauptthemen laut MEDLINE: Cell Movement, Fibroblast Growth Factor 1, Radiation Tolerance, Cell Proliferation. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI.
Abstract (Originalsprache)
Angiosarcoma is a rare refractory soft-tissue tumor with a poor prognosis and is treated by radiotherapy. The fibroblast growth factor 1 (FGF1) mutant, with enhanced thermostability due to several substituted amino acids, inhibits angiosarcoma cell metastasis, yet the mechanism of action is unclear. This study aims to clarify the FGF1 mutant mechanism of action using ISOS-1 mouse angiosarcoma cells. The wild-type FGF1 or FGF1 mutant was added to ISOS-1 cells and cultured, evaluating cell numbers over time. The invasive and migratory capacity of ISOS-1 cells was assessed by transwell analysis. ISOS-1 cell radiosensitivity was assessed by colony formation assay after X-ray irradiation. To examine whether mitogen-activated protein kinase (MEK) inhibitor counteracts the FGF1 mutant effects, a combination of MEK inhibitor and FGF1 mutant was added to ISOS-1 cells and cultured. The FGF1 mutant was observed to inhibit ISOS-1 cell proliferation, invasion and migration by sustained FGF1 signaling activation. A MEK inhibitor suppressed the FGF1 mutant-induced inhibition of proliferation, invasion and migration of ISOS-1 cells. Furthermore, the FGF1 mutant enhanced radiosensitivity of ISOS-1 cells, but MEK inhibition suppressed the increased radiosensitivity. In addition, we found that the FGF1 mutant strongly inhibits actin polymerization, suggesting that actin cytoskeletal dynamics are closely related to ISOS-1 cell radiosensitivity. Overall, this study demonstrated that in ISOS-1 cells, the FGF1 mutant inhibits proliferation, invasion and migration while enhancing radiosensitivity through sustained activation of the MEK-mediated signaling pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Regenerative Therapy Research Group, Department of Radiation Regulatory Science Research, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum Science and Technology (QST), 4-9-1 Anagawa,…
- Radiation Effect Research Group, Department of Accelerator and Medical Physics, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), 4-9-1 Anagawa, Inage-ku, Chiba 263-855…
- Department of Dermatology, Iwase General Hospital, 20 Kitamachi, Sukagawa-shi, Fukushima 962-8503, Japan.
Förderung
- JSPS KAKENHI
Zitieren
APA
Miura, T., Kado, J., Ashisuke, K., Masuzawa, M., & Nakayama, F. (2024). Sustained activation of the FGF1–MEK–ERK pathway inhibits proliferation, invasion and migration and enhances radiosensitivity in mouse angiosarcoma cells. Journal of Radiation Research. https://doi.org/10.1093/jrr/rrae021
Vancouver
Miura T, Kado J, Ashisuke K, Masuzawa M, Nakayama F. Sustained activation of the FGF1–MEK–ERK pathway inhibits proliferation, invasion and migration and enhances radiosensitivity in mouse angiosarcoma cells. Journal of Radiation Research. 2024. doi:10.1093/jrr/rrae021
BibTeX
@article{Miura2024,
author = {Miura, Taichi and Kado, Junko and Ashisuke, Kazuma and Masuzawa, Mikio and Nakayama, Fumiaki},
title = {Sustained activation of the FGF1–MEK–ERK pathway inhibits proliferation, invasion and migration and enhances radiosensitivity in mouse angiosarcoma cells},
journal = {Journal of Radiation Research},
year = {2024},
doi = {10.1093/jrr/rrae021}
}
EUVIMED